Hansa Biopharma AB (publ) (OTC:HNSBF) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET
Company Participants
Peter Nicklin – Chairman of the Board
Hitto Kaufmann – Chief R&D Officer
Evan Ballantyne – Chief Financial Officer
Renée Lucander – Chief Executive Officer
Conference Call Participants
Suzanne van Voorthuizen – Kempen
Douglas Tsao – H.C. Wainwright
Eric Yeung – William Blair
Chris Uhde – SEB
Operator
Good day and welcome to the Hansa Biopharma Interim Results and Q1 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Peter Nicklin, Chairman of the Board Hansa Biopharma. Please go ahead.
Peter Nicklin
Good afternoon and good morning everybody. Welcome to the Hansa Biopharma conference call to review our Q1 results for 2025. I’m Peter Nicklin Chairman of the Board of Hansa Biopharma. You’ll recollect in June this year, I actually reached my 30-year anniversary as Chairman of the Board.
Joining me today is Evan Ballantyne, Chief Financial Officer; Hitto Kaufmann, our Chief R&D Officer; and Renée Lucander our newly appointed CEO. Before we turn to the Q1 results you are most likely aware that earlier today we announced the departure of Søren Tulstrup, CEO of Hansa Biopharma effective immediately. Over the course of his tenure whilst with the organization Søren successfully navigated the company through several key milestones and financial rounds. The Board and I certainly appreciate his leadership and commitment to the company and wish him well for any future endeavors.
Later in the call we will hear from Renée who has been appointed as CEO effective immediately. Today is her first day at Hansa and while she is in the room with me here, I trust that you will agree that it
Read the full article here